Eosinophilic asthma is a subtype of asthma driven by an overabundance of eosinophils, a type of white blood cell that accumulates in the airways and causes persistent inflammation, tissue damage, and airway narrowing. It falls under the broader umbrella of “type 2 high” asthma, a category defined by the immune pathways fueling the disease rather than just the symptoms a patient experiences. Eosinophilic asthma tends to be more severe and harder to control with standard inhalers than other forms, but the upside is that its specific biology has made it a prime target for a new generation of injectable medications called biologics.
How Eosinophils Damage the Airways
Eosinophils are normally part of the immune system’s defense against parasites and certain infections. In eosinophilic asthma, though, these cells are recruited to the airways in large numbers where they cause collateral damage. Eosinophils carry preloaded granules packed with toxic proteins, including eosinophil cationic protein and major basic protein, which they release into surrounding tissue. These proteins are potent enough to erode the lining of the airways, trigger bronchial hyperreactivity, and promote structural changes in the airway walls, a process known as remodeling.1PubMed Central. Eosinophil granule proteins: form and function
Mouse studies that genetically removed eosinophil granule proteins found that without eosinophils, the major hallmarks of asthma pathology vanished: no epithelial damage, no hyperreactivity, no smooth muscle thickening, and no subepithelial fibrosis.1PubMed Central. Eosinophil granule proteins: form and function In humans, studies of stable asthma patients confirmed that activated eosinophils release these same toxic products, damaging airway epithelial cells even when the person is not in the middle of an acute attack.2PubMed. Airway eosinophilic inflammation, epithelial damage, and bronchial hyperresponsiveness in patients with mild-moderate, stable asthma This is one reason eosinophilic asthma can worsen over time even between flare-ups: the eosinophils are doing damage around the clock.
The chemical signal that keeps the whole process going is interleukin-5, or IL-5. This molecule acts as a master regulator for eosinophils, controlling their production in the bone marrow, pulling them into the airways, keeping them alive longer than they would otherwise survive, and triggering them to release their toxic granule contents.3PubMed Central. Interleukin-5 in the Pathophysiology of Severe Asthma IL-5 is the main reason biologic therapies for eosinophilic asthma have focused so heavily on this one pathway.
Why It Can Develop Without Allergies
Many people assume eosinophilic asthma is just a fancy name for allergic asthma, but the two overlap only partially. In allergic asthma, an allergen triggers a chain reaction involving IgE antibodies and T-helper-2 cells, which eventually recruit eosinophils. That pathway is real and common. But eosinophilic inflammation can also be driven by a completely separate arm of the immune system that does not require any allergen at all.
Group 2 innate lymphoid cells, known as ILC2s, lack the antigen-specific receptors that T cells use to recognize allergens. Instead, ILC2s respond to alarm signals released by the airway lining itself when it is damaged or irritated, such as by pollution, viral infections, or cigarette smoke. Once activated, ILC2s pump out the same inflammatory signals, including IL-5 and IL-13, that drive eosinophil recruitment and airway inflammation in an allergen-independent manner.4PubMed Central. The Functional Role of Group 2 Innate Lymphoid Cells in Asthma This explains why some people develop eosinophilic asthma in adulthood without any history of hay fever, eczema, or positive allergy tests.
The distinction matters clinically. Adult-onset eosinophilic asthma patients often have high total IgE levels in the blood but test negative for specific allergen sensitivities, which can confuse the diagnostic picture.5PubMed Central. Clinical profile of patients with adult-onset eosinophilic asthma If a doctor only looks for classic allergic triggers, this non-allergic eosinophilic pathway can be missed entirely.
What Eosinophilic Asthma Looks and Feels Like
The symptoms of eosinophilic asthma are the same ones you would expect in any asthma flare: wheezing, shortness of breath, chest tightness, and coughing. What distinguishes it clinically is not the symptoms themselves but their severity, their resistance to standard treatment, and the pattern of who gets them.
Studies of adult-onset eosinophilic asthma have identified a recognizable clinical profile. These patients tend to have poorly controlled asthma despite taking higher doses of inhaled corticosteroids. They experience frequent exacerbations, worse lung function, and are more likely to develop fixed airflow limitation, meaning part of the narrowing in their airways becomes permanent.5PubMed Central. Clinical profile of patients with adult-onset eosinophilic asthma Air trapping, where stale air gets stuck in the small airways, is also a common finding on imaging. Patients with high blood eosinophil counts at or above about 300 cells per microliter have been described as having a distinct phenotype marked by frequent exacerbations and poor prognosis.6European Respiratory Journal. Severe eosinophilic asthma: a roadmap to consensus
Before the era of biologic therapies, patients with this form of asthma often had a very poor quality of life. Many were dependent on repeated courses of oral corticosteroids, or even daily oral steroids, to keep exacerbations at bay.7ERJ Open Research. Management of the patient with eosinophilic asthma: a new era begins That steroid dependence brought its own cascade of problems: bone loss, weight gain, elevated blood sugar, cataracts, and immune suppression.
How Doctors Identify It
You cannot diagnose eosinophilic asthma by symptoms alone, because the symptoms overlap with every other form of asthma. The diagnosis hinges on biomarkers, measurable signals in the blood or airways that point to eosinophilic inflammation.
The most accessible test is a blood eosinophil count, drawn as part of a standard complete blood count. There is strong evidence linking the blood eosinophil count to clinical outcomes including lung function decline, exacerbation frequency, and response to both inhaled corticosteroids and biologic therapies.8PubMed Central. Measurement of Blood Eosinophils in Asthma and Chronic Obstructive Pulmonary Disease In one study of survivors of life-threatening asthma attacks, a blood eosinophil count at or above 1,200 cells per microliter was associated with roughly 80% higher risk of subsequent emergency visits or hospital admissions over the following years.9PubMed. Blood eosinophil count correlates with severity of respiratory failure in life-threatening asthma and predicts risk of subsequent exacerbations
Fractional exhaled nitric oxide, or FeNO, is another useful test. It measures a gas in your exhaled breath that rises when type 2 inflammation is active in the airways. It is cost-effective and done at the point of care, usually with a handheld device during a clinic visit.10PubMed Central. Update on the Role of FeNO in Asthma Management Head-to-head comparison studies have found that blood eosinophils and FeNO have comparable diagnostic accuracy for identifying airway eosinophilia, and both outperform total IgE. That accuracy holds across different asthma phenotypes, including severe, non-atopic, obese, and smoking-related asthma.11European Respiratory Journal. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes
The gold standard is induced sputum analysis, which directly counts eosinophils in airway secretions. But sputum induction is messy, requires lab processing, and is not widely available outside research centers. For most patients, a combination of blood eosinophils and FeNO gives doctors enough information to classify the asthma subtype and guide treatment decisions.
Biologic Therapies That Target the Source
The treatment landscape for eosinophilic asthma has changed dramatically with the development of biologic drugs. These are injectable antibodies, given every few weeks, that interrupt specific steps in the inflammatory cascade rather than broadly suppressing the immune system the way oral steroids do.
Because IL-5 is central to eosinophil biology, it was the first target. Two approved biologics, mepolizumab and reslizumab, work by binding directly to IL-5 itself, preventing it from reaching eosinophils.12PubMed Central. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma A third drug, benralizumab, takes a different approach: instead of blocking IL-5, it binds to the IL-5 receptor on the surface of eosinophils and tags those cells for destruction by the body’s own natural killer cells, a process called antibody-dependent cell-mediated cytotoxicity. The result is near-complete depletion of blood and tissue eosinophils.13PubMed Central. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
Dupilumab works at a different branch of the same inflammatory tree. Rather than targeting eosinophils directly, it blocks the receptor shared by two other inflammatory signals, IL-4 and IL-13, which contribute to mucus production, airway wall thickening, and eosinophil recruitment. In a large trial of patients with moderate-to-severe uncontrolled asthma and blood eosinophils of 300 or more per cubic millimeter, dupilumab reduced the rate of severe exacerbations by about two-thirds compared to placebo.14New England Journal of Medicine. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Going Further Upstream With TSLP Blockade
The newest addition to the biologic arsenal targets an even earlier step in the inflammatory process. Tezepelumab blocks thymic stromal lymphopoietin, or TSLP, a distress signal released by the airway lining that sits upstream of nearly all the downstream inflammatory players. By intercepting TSLP before it can activate ILC2s and other immune cells, tezepelumab reduces IL-5 and IL-13 levels and lowers both blood and airway eosinophil counts.15PubMed Central. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types
What makes tezepelumab conceptually different from the IL-5-targeting drugs is its breadth. Because TSLP sits upstream of multiple inflammatory pathways, blocking it has shown efficacy across different asthma phenotypes, not just eosinophilic asthma. It acts above all of the biomarkers clinicians currently measure.16PubMed. Tezepelumab in patients with allergic and eosinophilic asthma This is particularly relevant for the subset of patients whose asthma does not fit neatly into one biomarker-defined box.
Airway Remodeling and Why Timing Matters
One of the more concerning aspects of eosinophilic asthma is that it does not just cause reversible narrowing of the airways. Over time, the persistent presence of eosinophils drives structural changes: the basement membrane beneath the airway lining thickens, smooth muscle around the airways grows larger, and scar-like fibrosis develops. Eosinophils secrete molecules like transforming growth factor beta that actively promote this fibrosis.17PubMed. The eosinophil and airway remodelling in asthma Once these changes set in, they are not easily undone. This is what leads to the fixed airflow limitation seen in many patients with long-standing disease.
There is, however, encouraging evidence that biologic therapy can partially reverse some of these changes if given enough time. A recent study examining bronchial biopsies in severe eosinophilic asthma patients treated with mepolizumab found that basement membrane thickness dropped substantially within six months and continued to decrease at twelve months. Smooth muscle area in the airway wall also shrank over the same period.18CHEST. Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma These findings are from a small biopsy study, not a large randomized trial, so they should be interpreted cautiously. But they suggest that getting eosinophils under control early may help preserve lung architecture rather than just managing symptoms.
Conditions That Travel With Eosinophilic Asthma
Eosinophilic asthma rarely shows up alone. One of the most common companion conditions is chronic rhinosinusitis with nasal polyps. The same type 2 inflammatory process that drives eosinophils into the lungs also affects the sinuses, causing persistent congestion, loss of smell, facial pressure, and polyp growth. European expert consensus has identified nasal polyps as a critical comorbidity to evaluate in patients with severe eosinophilic asthma, along with allergic rhinitis and aspirin-exacerbated respiratory disease.19PubMed Central. Consensus from European experts on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps
Aspirin-exacerbated respiratory disease, sometimes called Samter’s triad, deserves special mention. It involves the combination of asthma, nasal polyps, and respiratory reactions triggered by aspirin or other nonsteroidal anti-inflammatory drugs. All three features are tied to eosinophilic inflammation in both the upper and lower airways.20PubMed Central. Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination If you have eosinophilic asthma and notice that aspirin or ibuprofen worsens your breathing, this triad is worth discussing with your doctor.
A rarer but important condition on the differential diagnosis is eosinophilic granulomatosis with polyangiitis, formerly known as Churg-Strauss syndrome. This is a systemic vasculitis, meaning the eosinophilic inflammation extends beyond the lungs to blood vessels and other organs. Distinguishing it from severe eosinophilic asthma can be difficult because the two share features like high blood eosinophils and severe airway disease. One study found that sputum GM-CSF, a specific immune signaling molecule, was significantly elevated in vasculitis patients compared to those with severe eosinophilic asthma alone, suggesting it may help differentiate the two.21PubMed Central. Severe Eosinophilic Asthma or Eosinophilic Granulomatosis With Polyangiitis: Potential Biomarkers for Novel Diagnostic Strategies
The Role of Fungal Sensitization
One trigger that often gets overlooked in discussions of eosinophilic asthma is fungal exposure. Sensitization to common environmental molds is disproportionately prevalent in patients with severe asthma. The immune response to fungal allergens involves the production of fungal-specific IgE antibodies along with the recruitment of eosinophils, neutrophils, and lymphocytes into the airways. The eosinophils then release their characteristic toxic proteins, including major basic protein and eosinophil peroxidase, amplifying tissue damage and inflammation.22PubMed Central. Association between sensitization to common fungi and severe asthma For patients whose eosinophilic asthma worsens in damp environments or during seasons of high mold counts, fungal sensitization testing can be a valuable piece of the diagnostic puzzle.
When Biologics Do Not Work as Expected
Biologic therapies have transformed the management of eosinophilic asthma, but they do not work for everyone. A subset of patients who appear to be ideal candidates based on their eosinophil counts either fail to improve or actually worsen on anti-IL-5 therapy. Understanding why is an active area of research.
One emerging explanation involves autoimmune phenomena in the airways. Researchers found that patients who responded poorly to anti-IL-5 antibodies were more likely to have autoantibodies in their sputum directed against eosinophil peroxidase. Those who worsened on therapy also showed signs of complement activation and deposition of immune complexes in their airway secretions, suggesting an autoimmune-driven process that anti-IL-5 drugs simply do not address.23PubMed. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena For these patients, targeting eosinophils alone may be insufficient, and identifying these autoimmune markers before starting therapy could help predict who will benefit and who might need a different approach entirely.
Is Depleting Eosinophils Safe Long-Term?
A reasonable question for anyone considering biologic therapy is whether wiping out eosinophils leaves you vulnerable to infections. Eosinophils evolved primarily to fight parasitic worms, so the main theoretical concern has been helminth infections. In the large clinical trials of benralizumab, which nearly eliminates circulating eosinophils, no helminth infections were reported across hundreds of global study sites, including locations in South America, Southeast Asia, and sub-Saharan Africa where such infections are more common.13PubMed Central. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab That is reassuring, but it comes with a caveat: the trial populations were still mostly from countries with low parasite burden. For patients living in areas where helminth exposure is a genuine everyday risk, the safety profile may differ, and this is an area where data remain thin.
Beyond helminths, overall infection rates in the biologic trials have generally been comparable between treatment and placebo groups. Eosinophils appear to be far less important for defending against bacteria and viruses than they are for fighting parasites, so driving their numbers down has not opened a noticeable gap in immune defense in the populations studied so far. The larger concern with any long-term biologic is not immune suppression but rather the open question of what happens when a drug is used for decades. These medications were approved relatively recently, and the longest follow-up data still span only a handful of years.